Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

BACKGROUND: The primary objective was to study the antitumor activity of prolonged subcutaneous dosing of systemic 852A, a Toll-like receptor-7 agonist (TLR-7), in recurrent breast, ovarian and cervix cancer. Secondary objectives included assessment of safety and immune system activation. METHODS: A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Geller, Melissa A., Cooley, Sarah, Argenta, Peter A., Downs, Levi S., Carson, Linda F., Judson, Patricia L., Ghebre, Rahel, Weigel, Brenda, Panoskaltsis-Mortari, Angela, Curtsinger, Julie, Miller, Jeffrey S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4098785/
https://ncbi.nlm.nih.gov/pubmed/20820775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-010-0914-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares